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Abstract
As part of a continued search for more efficient anti-HIV-1 drugs, we are focusing on the possibility
that small molecules could efficiently inhibit HIV-1 replication through the restoration of p53 and
p21WAF1 functions, which are inactivated by HIV-1 infection. Here we describe the molecular
mechanism of 9-aminoacridine (9AA) mediated HIV-1 inhibition. 9AA treatment resulted in
inhibition of HIV LTR transcription in a specific manner that was highly dependent on the presence
and location of the amino moiety. Importantly, virus replication was found to be inhibited in HIV-
1 infected cell lines by 9AA in a dose-dependent manner without inhibiting cellular proliferation or
inducing cell death. 9AA inhibited viral replication in both p53 wildtype and p53 mutant cells,
indicating that there is another p53 independent factor that was critical for HIV inhibition.
p21WAF1 is an ideal candidate as p21WAF1 levels were increased in both p53 wildtype and p53
mutant cells, and p21WAF1 was found to be phosphorylated at S146, an event previously shown
to increase its stability. Furthermore, we observed p21WAF1 in complex with cyclin T1 and cdk9
in vitro, suggesting a direct role of p21WAF1 in HIV transcription inhibition. Finally, 9AA treatment
resulted in loss of cdk9 from the viral promoter, providing one possible mechanism of
transcriptional inhibition. Thus, 9AA treatment was highly efficient at reactivating the p53 –
p21WAF1 pathway and consequently inhibiting HIV replication and transcription.
Introduction
HIV-1 infection results in the alteration of numerous host
factors and signaling cascades [1]. In particular, it has
been demonstrated that the p53 pathway plays an impor-
tant role in HIV-1 infection [2,3]. p53 is critical for pro-
tecting the integrity of the genome through regulating
apoptosis [4-9] and the cell cycle, at both G1/S [10-14]
and G2/M checkpoints [15-19]. Wild-type p53 has the
ability to be a potent suppressor of HIV-1 Tat transcrip-
tional activity [20,21], whereas mutant p53 can activate
HIV-1 transcription [22,23]. An RGD-containing domain
of Tat protein, Tat (65-80), was shown to play an impor-
tant role in regulating the proliferative functions of a vari-
ety of cell lines, including a human adenocarcinoma cell
line, A549. p53 activity was greatly reduced when cells
were treated with Tat-(65–80) [24]. On the other hand,
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Tat efficiently inhibits p53 transcriptional activity through
blocking K320 acetylation [25]. These above observations
are at least partially explained by the discovery that Tat
binds directly to p53 through the p53 dimerization
domain [26]. A model has been suggested where p53
could become inactivated in HIV-1 infected cells through
binding to Tat and subsequently losing its ability to trans-
activate its downstream target gene p21WAF1 [27]. While
the interplay between p53 and HIV-1 Tat has been clearly
demonstrated in vitro by a number of researchers, the in
vivo interaction is less clearly defined and requires further
analysis. Collectively, these observations indicate the pos-
sible role of p53 in the control of HIV-1 replication pat-
terns and proviral latency [22].
One of the most well characterized transcriptional targets
of p53 is the p21WAF1 gene. p21WAF1 was simultane-
ously characterized by a number of different researchers;
it has been described as a target of p53 transactivation, a
cyclin/cyclin-dependent kinase (cdk) inhibitor and a pro-
tein that is expressed in senescent fibroblasts [28-31]. In
addition to its most well-known role as a cdk inhibitor
(CKI) that can lead to cell cycle arrest, p21WAF1 is also
well recognized to be involved in a variety of other physi-
ological functions. These include the promotion of differ-
entiation as well as the imposition of cellular senescence
[32,33]. The anti-proliferative functions of p21WAF1 are
associated with its ability to bind to PCNA and block DNA
synthesis. Nuclear p21WAF1 also participates in regulat-
ing several transcriptional responses, as well as regulating
DNA methylation [34,35]. While in the cytoplasm
p21WAF1 also has important pro-proliferative and sur-
vival functions including promoting the formation of cyc-
lin D/cdk4, 6 complexes [36-38] and negatively regulating
Fas-mediated apoptosis through the inactivation of pro-
caspase 3 [34,35].
As the regulation of the p53 and p21WAF1 pathways by
HIV-1 infection has become a point of great interest, it
might be possible to combat HIV-1 infection through the
restoration of the p53 and p21WAF1 pathways using
small molecules, such as 9-aminoacridine (9AA). 9AA was
originally identified as an anti-bacterial agent, but more
recently has gained notice as a potential treatment for can-
cer, viral, and prion diseases [39-41]. Enthusiasm for 9AA
was initially dampened due to observed toxicity that was
suggested to be due to DNA intercalating properties and
possible topoisomerase II poisoning [42-44]. However,
later studies have demonstrated that 9AA can be utilized
in a selective manner, especially for virally infected cells.
In a 2008 study, up to 20 M 9AA was utilized with no
toxicity observed in uninfected cell lines or PBMCs [45].
In addition, an independent group demonstrated that
9AA treatment did not induced phosphorylation of his-
tone H2A.X or activate the DNA response kinases ATM or
ATR, all of which are indicators of DNA damage [41]. 9AA
was not found to cause DNA damage by poisoning topoi-
somerase II as had been previously suggested [41]. There-
fore, it appears that 9AA activates p53 through a
mechanism different than DNA damage induced p53.
9AA treatment of renal carcinoma cells and HTLV-1
infected T-cells demonstrated NF-B inhibition and p53
activation, with NF-B inhibition being upstream of p53
activation [41,45,46]. 9AA triggered cell death is depend-
ent on p53, as p53 siRNA blocks 9AA induced cell death
[45]. More recently, Guo et al. demonstrated through pro-
teomics analysis downregulation of p110, the catalytic
subunit of the phosphoinositide 3-kinase (PI3K) family
upon 9AA treatment of renal carcinoma cells [47]. Follow-
up studies indicated that AKT and the mammalian target
of rapamycin (mTOR) signaling were inhibited, which
contributed to p110 downregulation, and possibly p53
and NF-B alterations.
Previously we have shown that 9AA efficiently reactivates
the p53 and p21WAF1 pathways in HIV-1 infected cells
[46]. Specifically, we observed increased S15 phosphor-
ylation of p53 and increased p21WAF1 protein levels.
p53-pS15 was not detected in complex with Tat, freeing
p53 from Tat inhibition. Importantly, virus replication
was found to be inhibited in HIV infected PBMCs by 9AA
in a dose-dependent manner. Here we investigate further
the mechanism of 9AA HIV-1 inhibition. We show that
9AA treatment resulted in inhibition of Tat dependent
HIV-1 transcription, without inhibition of cellular prolif-
eration. Using various 9AA derivatives we determined that
the amino moiety of 9AA is critical for the observed tran-
scriptional inhibition. We observed for the first time
p21WAF1 in complex with p-TEFb (cyclin T1 and cdk9) in
vitro, suggesting a role of p21WAF1 in HIV-1 transcription
and 9AA mediated inhibition of viral transcription.
Finally, we observed loss of the critical transcriptional
cofactor, cdk9, from the LTR following 9AA treatment,
indicating that this is one possible mechanism of 9AA
mediated viral inhibition. Thus, 9AA treatment is highly
efficient at reactivating p53 and p21WAF1 pathways and
inhibiting HIV replication.
Materials and methods
Cell Culture
ACH2 and J1.1 are latently HIV-1 infected T-cell lines.
ACH2, J1.1, CEM, and Jurkat cells were grown in RPMI-
1640 media containing 10% fetal bovine serum (FBS),
1% L-glutamine, and 1% streptomycin/penicillin. TZM-bl
cells were grown in Dulbecco's modified Eagle's medium
supplemented with 10% FBS, 1% L-glutamine, and 1%
streptomycin/penicillin. All cells were incubated at 37°C
and 5% CO2.Virology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
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Small Molecule Compounds and Antibodies
9-aminoacridine was obtained from Sigma, 2-aminoacri-
dine and 4-aminoacridine from KaironKem, acridine
hydrochloride from TCI, and 4-aminoquinoline from
Tyger Scientific. p21WAF1, phospho-p21WAF1 (S146),
cdk2, cyclin T, and actin antibodies were obtained from
Santa Cruz Biotechnology. Cdk9 antibody was obtained
from Biodesign International. p53, phospho-p53 (S15),
AKT (pan), phospho-AKT (S473), phospho-AKT (T308),
GSK3- (pan), phospho-GSK3- (S9) antibodies were
obtained from Cell Signaling.
CAT Assay
Plasmids (LTR-CAT and/or CMV-Tat) were transfected by
electroporation using a Bio-Rad Gene Pulser (Bio-Rad,
Richmond, CA) at 960 F and 230 volts. Two hours after
transfection drug treatment was initiated. After 48 hours,
cells were lysed and chloramphenicol acetyltransferase
(CAT) activity was determined. Briefly, a standard reac-
tion was performed by adding the cofactor acetyl coen-
zyme A to a microcentrifuge tube containing cell extract
(50 ug) and radiolabeled (14C) chloramphenicol in a final
volume of 30 l and incubating the mixture at 37°C for 1
hour. The reaction mixture was then extracted with ethyl
acetate and separated by thin-later chromatography on sil-
ica gel plates (Baker-flex silica gel thin-later chromatogra-
phy plates) in a chloroform-methanol (19:1) solvent. The
resolved reaction products were then detected by exposing
the plate to a PhosphoImager cassette.
Luciferase Assay
TZM-bl cells were transfected with pc-Tat (0.5 ug) using
the Attractene reagent (Qiagen) according to the manufac-
turers' instructions. TZM-bl cells contain an integrated
copy of the firefly luciferase gene under the control of the
HIV-1 promoter (obtained through the NIH AIDS
Research and Reference Reagent Program). The next day,
cells were treated with DMSO or the indicated compound.
Forty-eight hours post drug treatment, luciferase activity
of the firefly luciferase was measured with the BrightGlo
Luciferase Assay (Promega). Luminescence was read from
a 96 well plate on an EG&G Berthold luminometer.
Chromatin Immunoprecipitation Assay (ChIP)
ACH2 cells were treated with 2.5 uM 9AA and processed
48 hours later for ChIP. For ChIP, approximately 5 × 106
cells were used per IP. Cells were cross-linked with 1.0%
formaldehyde at 37°C for 10 minutes, pelleted, washed,
and cells lysed using SDS lysis buffer (1% SDS, 10 mM
EDTA, 50 mM Tris-HCl, pH 8.0, one tablet complete pro-
tease inhibitor cocktail per 50 ml) on ice for 10 mins.
Cells were sonicated on ice for 6 cycles to obtain an aver-
age DNA length of 500 to 1200 bp. Lysate was clarified by
centrifugation at 14,000 rpm for 10 minutes at 4°C.
Supernatant was then diluted 10 fold in ChIP dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl) and pre-
cleared with a mixture of protein A/G agarose (blocked
previously with 1 mg/ml salmon sperm DNA and 1 mg/
ml BSA) at 4°C for 1 hour. Pre-cleared chromatin was
incubated with 10 g of antibody at 4°C overnight. Next
day, 60 l of a 30% slurry of blocked protein A/G agarose
was added and complexes incubated for 2 hours. Immune
complexes were recovered by centrifugation and washed
once with low salt buffer (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl),
twice with high salt buffer (0.1% SDS, 1% Triton X-100 2
mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl), once
with LiCl buffer (0.25 M LiCl, 1% NP-40, 1% deoxycho-
late, 1 mM EDTA, 10 mM Tris-HCl, pH 8.0), and once
with TE buffer. Immune complexes were eluted twice with
elution buffer (1% SDS, 0.1 M NaHCO3) and incubating
at room temperature for 15 minutes on a rotating wheel.
Cross-links were reversed by adding 20 l of 5 M NaCl and
incubating elutes at 65°C overnight. The next day, protei-
nase K (100 g/ml final concentration) was added and
samples incubated at 55°C for 1 hour. Samples were
extracted with phenol:chloroform twice and ethanol pre-
cipitated overnight. Pellets were then washed with 70%
ethanol, dried, resuspended in 50 l of TE, and assayed by
PCR. Thirty-five cycles of PCR were performed in 50 l
with 10 l of immunoprecipitated material, 0.1 M of
primers, 0.2 mM dNTPs, and 1.0 unit of Taq DNA
polymerase. Finally, PCR products were electrophoresed
on 2% agarose gels and visualized by ethidium bromide
staining.
Western Blot Analysis
Cell extracts were resolved by SDS PAGE on a 4-20% tris-
glycine gel (Invitrogen). Proteins were transferred to
Immobilon membranes (Millipore) at 200 mA for 2
hours. Membranes were blocked with Dulbecco's phos-
phate-buffered saline (PBS) 0.1% Tween-20 + 3% BSA.
Primary antibody against specified antibodies was incu-
bated with the membrane in PBS + 0.1% Tween-20 over-
night at 4°C. Membranes were washed two times with
PBS + 0.1% Tween-20 and incubated with HRP-conju-
gated secondary antibody for one hour. Presence of sec-
ondary antibody was detected by SuperSignal West Dura
Extended Duration Substrate (Pierce). Luminescence was
visualized on a Kodak 1D image station.
RT Assays
Supernatants from ACH2 and J1.1 cells were collected to
test for the presence of virus on day 7 post 9AA treatment.
Viral supernatants (10 l) were incubated in a 96-well
plate with reverse transcriptase (RT) reaction mixture con-
taining 1× RT buffer (50 mM Tris-HCl, 1 mM DTT, 5 mM
MgCl2, 20 mM KCl), 0.1% Triton, poly(A) (1 U/ml),
pd(T) (1 U/ml), and [3H]TTP. The mixture was incubatedVirology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
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overnight at 37°C, and 10 ml of the reaction mix was
spotted on a DEAE Filtermat paper, washed four times
with 5% Na2HPO4, three times with water, and then dried
completely. RT activity was measured in a Betaplate coun-
ter (Wallac, Gaithersburg, MD).
GST Pulldown Assays
GST tagged proteins were purified as described previously
[46]. GST-p21 (1 g), GST-p21 (N) (1 g), GST-p21 (C)
(1 g), or GST (1 g) proteins were added to 2 mg of CEM
extracts from various cell lines and rotated overnight at
4°C. The next day complexes were washed twice with
TNE150 + 0.1% NP-40 and once with TNE50 + 0.1%NP-40.
Complexes were run on 4–20% Tris-glycine gel. Western
blots were performed with anti-cdk9 (Biodesign), anti-
cyclin T, and anti-cdk2 (Santa Cruz) antibodies.
MTT Assays
Five thousand cells were plated per well in a 96-well plate
and the next day cells were treated with various concentra-
tions of compounds (1, 10, 50 M) or DMSO. Forty-eight
hours later, 10 l MTT reagent (50 mg/ml) was added to
each well and plates incubated at 37°C for 2 hours. Next,
100 l of DMSO was added to each well and plate was
shaken for 15 minutes at room temperature. The assay
was read at 570 nM.
Results
9AA inhibits HIV-1 Tat dependent transcription
We have previously observed that 9AA inhibits viral repli-
cation [46]. We were therefore interested if 9AA could spe-
cifically inhibit Tat dependent transcription. To test this
hypothesis, CEM cells were transfected with HIV LTR-CAT
with and without Tat. Two hours after transfection, the
cells were treated with various concentrations of 9AA or
100 nM of flavopiridol as a positive control for transcrip-
tion inhibition. Cells were harvested 48 hours post treat-
ment and CAT assays performed. As expected,
Flavopiridol treatment decreased viral transcription (Fig-
ure 1A, lane 7). Interestingly, 9AA treatment also
decreased viral transcription in a dose dependent manner
(lanes 3–6). Based on this data we can estimate that the
IC50 of viral LTR Tat activated transcription inhibition by
9AA is approximately 250 nM. These results suggest that
the observed inhibition of viral replication could be due
at least in part to the ability of 9AA to inhibit viral tran-
scription.
To determine if viral transcription inhibition also
occurred on a fully chromatinized promoter, we utilized
TZM-bl cells, which have an integrated LTR-luciferase
reporter construct. TZM-bl cells were transfected with Tat
and treated with various concentrations of 9AA or 100 nM
flavopiridol the following day. Luciferase assays revealed
that 9AA inhibited LTR transcription in a dose dependent
manner, with 1 M showing greater than 50% inhibition
and 2.5 M showing complete transcriptional inhibition
(Figure 1B). We were interested if 9AA derivatives would
display similar transcriptional inhibition ability. Four
commercially available 9AA derivates were purchased
(Figure 1C). Compounds 2-aminoacridine (2AA) and 4-
aminoacridine (4AA) differ from 9AA only in the location
of the amino moiety, while acridine hydrochloride (AH)
lacks the amino group. 4-aminoquinoline (4AQ) retains
the amino moiety in the same position as 9AA, but lacks
the third aromatic ring. Luciferase assays performed with
these compounds indicated that the presence and loca-
tion of the amino moiety is critical for the activity of 9AA,
as both AH and 4AA did not inhibit HIV-1 transcription
(Figure 1D). Surprisingly, cells treated with 2AA exhibited
an increase in viral transcription at both 1 M and 10 M.
4AQ treated cells showed limited viral transcription inhi-
bition at 1 M and approximately 50% inhibition at 1
M. These results demonstrate the importance of both the
presence and location of the amino moiety for the activity
of 9AA and also show that, while improving 9AA activity,
the third aromatic ring is not essential. The inhibition
demonstrated by 9AA is specific to this class of com-
pounds, as other amino acridines did not display activity
to the same extent. In addition, they demonstrate that
9AA inhibits HIV-1 transcription in a specific manner.
9AA inhibits viral replication in cells with mutant p53
To determine the contribution of p53 to 9AA mediated
viral inhibition, viral replication was assessed in two dif-
ferent HIV-1 infected cell lines, J1.1 and ACH2, which
vary in their p53 status. While there has been a discord-
ance in the literature regarding p53 status in CEM cells
[48,49], which is the parental cell line of ACH2; in our
hands we have observed p53 DNA binding and activation
of downstream signals, therefore p53 is functional in
these cells. Conversely, Jurkat cells (parental cell line of
J1.1) are well accepted as being p53 mutant cells, with
R196X, T256A, D259G, and S260A mutations [49]. Both
of these cells produce little virus in the absence of stimu-
lation and therefore, supernatants were collected seven
days after treatment to measure viral replication. RT assays
indicated that viral replication was inhibited in both J1.1
and ACH2 cells at 5.0 M 9AA (Figure 2A). Cell viability
at seven days was unaffected in J1.1 cells, but decreased by
approximately 50% in ACH2 cells (Figure 2B). These
results suggest that the influence of 9AA on cellular viabil-
ity may be dependent on the status of p53 and/or cell type
dependent. We next examined the levels of p21WAF1 in
J1.1 cells upon 9AA treatment. Figure 2C indicates that
even though there is no detectable p53 in J1.1 cells,
p21WAF1 is still induced with low levels of 9AA, which is
similar to the results observed with ACH2 cells [44]. These
results are interesting as they indicated that 9AA is capable
of inhibiting viral replication in p53 mutant cells and thatVirology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
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9AA inhibits HIV-LTR transcription Figure 1 (see previous page)
9AA inhibits HIV-LTR transcription. A) CEM cells were transfected with 2.5 g HIV-LTR CAT and 0.5 g of pc-Tat by 
electroporation. Twenty-four hours post-transfection, cells were treated with DMSO, 9AA (0.1, 0.5, 1, or 2.5 M), or 100 nM 
Flavo (flavopiridol). Cells were harvested 48 hours post transfection and processed for CAT assays. CAT assays were per-
formed with 4 mM acetyl CoA, 5 l of 14C-chloramphenicol (40 mCi/mmole), 10 l of protein extracts, and 18 l of water. 
Reactions were carried out at 37°C for 30 minutes. Samples were extracted with ethyl acetate, dried, and separated by TLC. 
B) TZM-bl cells were transfected with 1.0 g of Tat and treated the next day with DMSO, 9AA (0.1, 0.5, 1, or 2.5 M), or 100 
nM flavopiridol. Cells were processed 48 hours post drug treatment for luciferase assays. Assays were performed in triplicate 
and an average value is shown plus standard deviation. C) Structures of 9AA and derivatives. D) TZM-bl cells were transfected 
with 1.0 g of Tat and treated the next day with DMSO, 1 or 10 M of 9AA, 2AA, 4AA, AH, 4AQ, or 100 nM flavopiridol. 
Cells were processed 48 hours post drug treatment for luciferase assays. Assays were performed in duplicate and an average 
value is shown.
9AA inhibits viral replication in cells with mutant p53 Figure 2
9AA inhibits viral replication in cells with mutant p53. HIV-1 infected (J1.1 and ACH2) T-cells were treated with 0.5, 1, 
and 5 M of 9AA. A) RT activity was determined by at seven day post treatment. B) Cell viability was determined by trypan 
blue staining (~100/sample) seven days post treatment. C) J1.1 cells were treated with DMSO, 1, 2.5, and 5 M 9AA and col-
lected after 48 hours. Western blots were performed with anti-p21WAF1, anti-p53, anti-p53-phospho-S15, and actin antibod-
ies.
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p21WAF1 is still induced by 9AA in the absence of func-
tional p53.
9AA does not inhibit proliferation in uninfected cells
As HIV-1 replicates more efficiently in proliferating cells
and inhibiting cellular proliferation of uninfected cells
could result in toxicity, we accessed whether 9AA treat-
ment could be inhibiting cell proliferation. To this end,
MTT assays were performed (Figure 3). MTT assays meas-
ure the reduction of the yellow tetrazolium MTT reagent
(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide). Reduction occurs only by metabolically active
cells and thus a reduced reading indicates decrease prolif-
eration and possibly reduced viability. MTT assays were
performed on uninfected and infected cells treated with
either 9AA (panel A), 2AA (panel B), 4AA (panel C), or
AH (panel D). Results indicate that up to 50 M of 9AA
had little to no effect on uninfected cells, but decreased
cellular proliferation at 10 and 50 M was observed for
HIV-1 infected cells. It is important to note that low 9AA
concentrations have been used consistently to observed
viral inhibition, which is below the level at which cellular
proliferation is being inhibited. Interestingly, all of the 3-
ring 9AA derivatives had no effect on cellular proliferation
in either uninfected or infected cells (panels B-D). There-
fore, these results indicate that 9AA does not inhibit cellu-
lar proliferation in uninfected cells. These results also
confirm that the inhibition of proliferation observed in
the infected cells is dependent on the presence and loca-
tion of the amino moiety of 9AA.
9AA induces AKT activity and stabilization of p21WAF1
Recently, Guo et al. demonstrated downregulation of
p110, the catalytic subunit of the phosphoinositide 3-
kinase (PI3K) family upon 9AA treatment of renal carci-
noma cells [47]. Follow-up studies indicated that AKT and
mammalian target of rapamycin (mTOR) signaling were
inhibited, which contributed to p110 downregulation,
and possibly p53 and NF-B alterations. Therefore, we
were interested to see if similar events were occurring
upon 9AA treatment in HIV-1 infected cells. Surprisingly,
we observed a varying increase in AKT phosphorylation at
both T308 and S473 in either ACH2 and J1.1 cells follow-
ing 9AA treatment (Figure 4), indicating that AKT was acti-
vated upon 9AA treatment. C81 HTLV-1 infected cells are
used as a positive control as AKT is active and phosphor-
9AA does not inhibit proliferation of uninfected cells Figure 3
9AA does not inhibit proliferation of uninfected cells. Uninfected (CEM and Jurkat) and HIV-1 infected (ACH2 and J1.1) 
T-cells were treated with DMSO, 1, 10, or 50 M of A) 9AA, B) 2AA, C) 4AA, D) AH. Cell proliferation/viability was deter-
mined by MTT assays. Treatments were performed in triplicate and samples analyzed at 48 hours.
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ylated in HTLV-1 infected cells in a Tax dependent manner
[50]. These phosphorylation events were especially pro-
nounced in J1.1 cells as compared to uninfected Jurkat
cells (compare lanes 10 and 13 to lanes 14 and 17). AKT
is phosphorylated at both T308 and S473 to induce
enzyme activation, with T308 being phosphorylated by
PDK1 [51,52] and S473 by mTOR [53-56]. To confirm
that AKT was activated we examined a downstream sub-
strate of AKT, GSK3- [57]. GSK3- is phosphorylated by
AKT on S9, inhibiting the activity of GSK3- and regulat-
ing downstream events such as glycogen synthesis and -
catenin signaling [58,59]. Total GSK3- levels remained
constant in Jurkat and J1.1 cells, but decreased upon 9AA
treatment in ACH2 and CEM cells. Interestingly, p-GSK3-
 levels were increased in Jurkat, J1.1 and ACH2 cells,
while CEM cells display no p-GSK-3 with or without 9AA
treatment. We next examined an upstream event of AKT
activation, PDK1 phosphorylation at S241, which is an
autophosphorylation event necessary for PDK1 activation
[60]. PDK1 exhibited increased phosphorylation and thus
activation in J1.1 cells, but only a modest increase in CEM,
ACH2, and Jurkat cells. Finally, we examined p21WAF1
phosphorylation on S146, which has been shown to be
phosphorylated by AKT, resulting in increased p21WAF1
stability [61]. Both ACH2 and J1.1 cells displayed
p21WAF1 phosphorylation following 9AA treatment.
Collectively these results indicate that AKT activity is
increased following 9AA treatment, resulting in increased
p21WAF1 phosphorylation, which could aid in stabiliza-
tion of p21WAF1. This phosphorylation was observed in
both p53 wildtype and p53 mutant cells.
p21WAF1 binds to cyclin T and cdk9 in vitro
As 9AA treatment resulted in increased p21WAF1 expres-
sion and stability, we were interested to determine if
p21WAF1 could bind to the cyclin T/cdk9 complex since
this is one of the key factors regulating HIV-1 promoter
activity. To this end, we performed a GST-pulldown assay.
GST, GST-p21, GST-p21 C-terminus [GST-p21 (C)], and
GST-p21 N-terminus [GST-p21 (N)] were incubated with
CEM cellular extracts overnight at 4°C. The next day, com-
plexes were bound to glutathione sepharose beads,
washed with TNE buffer, analyzed by SDS-PAGE, and
western blotted with anti-cyclin T and cdk9 antibodies.
Full length p21WAF1 as well as the C- and N-terminal
regions of p21WAF1 were observed in complex with cyc-
lin T (Figure 5A). The strongest binding was observed with
the N-terminal region. Interestingly, the N-terminal
region of p21WAF1 was also observed in complex with
cdk9. This data is in agreement with other studies indicat-
ing that the N-terminal of p21WAF1 contains cyclin and
cdk binding domains, whereas the C-terminal only con-
tains a cyclin binding site [62,63]. As a positive control,
we also tested for cdk2 and p21WAF1 binding (Figure
5B). Therefore, these results suggest that p21WAF1 is a
component of the p-TEFb complex.
9AA induces AKT activity and stabilization of p21WAF1 Figure 4
9AA induces AKT activity and stabilization of p21WAF1. Uninfected (CEM and Jurkat) and HIV-1 infected (ACH2 and 
J1.1) T-cells were treated with DMSO, 1, 2.5, or 5 M of 9AA and collected 48 hours later. Western blot analysis was per-
formed for Akt (pan), phospho-Akt (S473), phospho-Akt (T308), GSK3- (pan), phospho-GSK3- (S9), phospho-PDK1 (S241), 
phospho-p21WAF1 (S146), and actin.
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9AA treatment results in loss of cdk9 from the viral LTR
Due to the observed binding of p21WAF1 with the pTEFb
complex and the importance of cdk9 in HIV-1 transcrip-
tion, we performed ChIP experiments to determine if
cdk9 binding at the LTR was altered upon 9AA treatment.
ACH2 cells were treated with either DMSO or 9AA and
collected 48 hours later. Results indicated that 9AA treat-
ment results in a dramatic loss of cdk9 from the LTR (Fig-
ure 6). In addition, we observed a reduction in the levels
of histone H3-phospho-S10 levels upon 9AA treatment.
These results suggest that 9AA treatment alters LTR bind-
ing proteins to induce transcriptional inhibition.
Discussion
In this study we have demonstrated that 9AA is an HIV-1
transcriptional inhibitor that acts without inducing cell
death or inhibiting cellular proliferation of uninfected
cells. Interestingly, we observed 9AA inhibition of HIV-1
replication in both p53 wildtype and p53 mutant cells.
However, in both cell types p21WAF1 levels were
increased following 9AA treatment. Unexpectedly, we
found increased AKT activity upon 9AA treatment as well
as phosphorylation of p21WAF1 at S146, a known target
of AKT, which induces p21WAF1 stability. We also
observed p21WAF1 in complex with cdk9/cyclin T in vitro,
suggesting that p21WAF1 may act as an inhibitor of cdk9/
cylin T1 kinase activity. Finally, we found that cdk9 was
removed from the viral LTR following 9AA treatment,
indicating one mechanism for loss of viral transcription.
The interplay between p53 and HIV-1 is of significant
interest to the HIV-1 field. Specifically, p53 and Tat antag-
onize each other, resulting in inhibition of Tat transcrip-
tion by p53 and downregulation of p53 dependent
transcription by Tat [21]. In addition, the activation of
p53 is known to induce apoptosis in response to gp120
[2,64,65], where cell death can be induced by through
mTOR-mediated phosphorylation of p53 on S15 and sub-
sequent phosphorylation of p53 on S46 [65,66]. p53
phosphorylation on S15 was observed following 9AA
treatment, however cell death was not observed at low lev-
els of compound treatment. S15 phosphorylation is a
priming event necessary for other p53 post-translational
modifications, with the end result of p53 activation.
p21WAF1 binds to cyclin T and cdk9 in vitro Figure 5
p21WAF1 binds to cyclin T and cdk9 in vitro. One g of GST, GST-p21, GST-p21 (C), or GST-p21 (N) were added to 1 
mg of CEM cell lysates and allowed to bind overnight. The next day, complexes were bound to glutathione sepharose beads, 
washed, and analyzed by SDS-PAGE, followed by western blotting for cyclin T and cdk9 (Panel A) or cdk2 (Panel B). ext = 
Extract.
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Therefore, our results indicate that 9AA treatment acti-
vates p53 and inhibits HIV-1 without inducing apoptosis.
Conversely there has also been data indicating that knock-
down of p53 through RNA interference results in a
marked reduction in Tat-induced transcription [67]. One
potential explanation for the discrepancy is that the above
mentioned study examined acutely infected cells, whereas
many of the other investigators used chronic or latently
infected models, where the status of p53 is unknown. In
addition, our current results point toward both p53
dependent and p53 independent activation of p21Waf1
by 9AA treatment. We believe that p21Waf1 may be the
key protein in regulating cyclin/cdk complexes in these
chronically or latently infected cells.
Recently, Zhang et al. investigated p21WAF1 as a potential
molecular barrier for HIV-1 infection of stem cells [68].
Hematopoietic stem cells were previously demonstrated
to be highly resistant to HIV-1 infection [69-71]. In this
study, p21WAF1 was revealed to restrict HIV-1 infection
in primitive hematopoietic cells. By knockdown of the
endogenous p21WAF1 levels using siRNAs, the stem cells
became highly susceptible to HIV-1 infection. Further, it
was shown that the effect of p21WAF1 is specific as the
silencing of other p21WAF1 related proteins, p27 and p18
had no effect on HIV-1 infection. Based on these results it
was suggested that p21WAF1 may be a possible restriction
factor, like TRIM5 and APOBEC3G genes [72-76]. Inter-
estingly, previous research showed that high-titer infec-
tion of HIV-1 in T lymphocytes resulted in a loss of the
endogenous p21WAF1 [27], further demonstrating the
importance of p21WAF1 in HIV-1 biology.
Our results indicate that p21WAF1 can be induced upon
9AA treatment independently of p53. In fact, p21WAF1
can be induced by a wide array of transcription factors
independent of p53 including Sp1/Sp3, BRCA1, E2F-1/
E2F-3, Smad3/4, STAT1, STAT3, STAT5, C/EBP, and C/
EBP [77]. In addition, there are a number of transcrip-
tion factors that are involved in the repression of
p21WAF1 transcription including c-myc, c-jun, and Id1
[78]. A number of theses factors also have an influence on
HIV-1 transcription, including Sp1, C/EBPs, and c-myc
[79]. Therefore future studies will be focused on identify-
ing signaling pathways that are altered upstream of
p21WAF1 induction following 9AA treatment.
Surprisingly we observed an increased in AKT activity and
GSK3- phosphorylation following 9AA treatment in
both p53 wildtype and p53 mutant cells. At first glance
these results seemed puzzling; however there are a
number of mechanisms that could explain this observa-
tion. MDM2 is a p53 transcriptional target that also func-
tions in a feedback loop to regulate p53 levels through
inducing p53 proteasomal degradation [80-84]. In order
for MDM2 to target p53 to the proteasome it must be
phosphorylated within its central domain [85]. Interest-
ingly, MDM2 is phosphorylated by GSK3, resulting in
decreased p53 stability [86]. In addition, Boehme et al.
found that p53 is stabilized following DNA damage due
to DNA PK mediated activation of AKT, phosphorylation
and inhibition of GSK3, and consequently inhibition of
MDM2 [87]. Therefore in p53 wildtype cells, AKT activa-
tion could serve to increase the stability of p53 through
the downstream inhibition of MDM2. In both p53
wildtype and mutant cells we observed p21WAF1 phos-
phorylation at S146, which has been shown to enhance
stability of p21WAF1 as well as disrupt the interaction of
p21WAF1 with PCNA [61,88]. S146 phosphorylation was
originally described as an AKT event [61], but can also be
induced by PKC which is downstream of AKT [89]. Hela
cells treated with siRNA against PKC display reduced
p21WAF1 stability [89]. Finally, mTOR has been shown
to phosphorylate S15 of p53 [64,65], which is enhanced
following 9AA treatment. Our results demonstrate that
two substrates of mTOR, p53 S15 and AKT S473 display
increased phosphorylation following 9AA treatment. Col-
lectively, these results suggest that AKT and mTOR are acti-
vated following 9AA treatment and may help stabilize
p53-p21WAF1 activation.
Cyclin T/cdk9 are key factors regulating HIV-1 promoter
activity, forming the main components of the p-TEFb
complex. p-TEFb, the positive elongation factor, is critical
for both transcriptional initiation and elongation,
through the phosphorylation of RNA polymerase II (RNA
Pol II) C-terminal domain (CTD) [90-99]. p-TEFb is a
multi-protein complex that can be found in two distinct
complexes, a small highly active p-TEFb that contains
cdk9 with a cyclin partner (cyclin T1, T2a, T2b, or K), and
a large inactive p-TEFb complex [100-103]. Components
of the large complex, 7SK small nuclear RNA (snRNA) and
the hexamethylene bisacetamide-induced protein 1
(HEXIM1), have been shown to inhibit p-TEFb activity
[100,102,104,105]. Most cdks are inhibited by either the
INK (p15, p16, p18, and p19) or Cip/Kip (p21WAF1, p27,
p57) family of cdk inhibitors [31,106-112]. To date, cdk9
has not been shown to be inhibited by either cdk inhibitor
family. Here for the first time, we demonstrate p21WAF1
binding to cdk9 and cyclin T in vitro. It is possible that
p21WAF1 needs to be in a phosphorylated state to allow
binding to cdk9/cylin T as was observed following 9AA
treatment. Indeed, it is known that phosphorylation of
p21WAF1 influences its binding partners, with phospho-
rylation of S146 disrupting binding to PCNA [88]. It
remains to be seen whether phosphorylation of p21WAF1
increases the binding to cdk9, cyclin T1, or to both, as
p21WAF1 interacts with both cdk and cyclin partners
through different motifs [62]. p21WAF1 has a short half
life of approximately one hour, therefore phosphoryla-Virology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
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tion of S146 could also influence the formation of a
p21WAF1-p-TEFb complex through stabilizing p21WAF1.
We hypothesize that p21WAF1 inhibits cyclin T/cdk9
activity resulting in inhibition of RNA Pol II CTD phos-
phorylation and HIV-1 transcription. Along these lines,
following 9AA treatment we observed loss of cdk9 at the
viral promoter. We have also previously shown that 9AA
treatment inhibits cyclin E/cdk2 kinase activity [46].
Therefore, a combination of cyclin E/cdk2 and cyclin T/
cdk9 inhibition by increased p21WAF1 levels would
severely diminish the levels of phosphorylated RNA Pol II
CTD and inhibit HIV-1 transcription (Figure 7).
Finally, we have begun to dissect particular structural fea-
tures that are critical for 9AA's mechanism of action
through the use of 9AA derivatives. Our studies have
shown that the amino moiety is critical for transcriptional
inhibition as loss or movement of this moiety results in
loss of 9AA activity. Furthermore, removal of the third
aromatic ring of 9AA only partially diminishes 9AA's
activity, indicating that it is not a critical structural feature.
Future studies will further define the structure activity
relationships of this class of molecules in search for a
more potent and specific transcriptional inhibitor.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
IG performed western blot analysis, GST-pulldowns, and
luciferase assays. RE performed luciferase assays. EA per-
formed drug treatment studies. LC performed ChIP exper-
iments. RD and WC performed western blot analysis. CD
provided essential advice in regards to the 9AA derivatives
to test. FK aided in the preparation of the manuscript and
in experimental design. KK coordinated the research and
experimental design, as well as wrote the manuscript.
Acknowledgements
We would like to thank the members of the Kashanchi lab for experiments 
and assistance with the manuscript. We would also like to thank Dr. Ani-
ndya Dutta (University of Virginia) for the GST-p21WAF1 plasmid con-
structs.
References
1. Ptak RG, Fu W, Sanders-Beer BE, Dickerson JE, Pinney JW, Robert-
son DL, Rozanov MN, Katz KS, Maglott DR, Pruitt KD, et al.: Cata-
loguing the HIV type 1 human protein interaction network.
AIDS Res Hum Retroviruses 2008, 24:1497-502.
2. Castedo M, Perfettini JL, Piacentini M, Kroemer G: p53-A pro-apop-
totic signal transducer involved in AIDS.  Biochem Biophys Res
Commun 2005, 331:701-6.
Model of 9AA induced activation of p21WAF1 in HIV-1 infected cells Figure 7
Model of 9AA induced activation of p21WAF1 in HIV-1 infected cells. In HIV-1 infected cells, p53 is inactivated 
through the binding to Tat. Upon 9AA treatment, p53 becomes phosphorylated at Ser15, resulting in loss of Tat binding and 
transcription of p53 dependent promoters, specifically p21WAF1. p21WAF1 protein levels are increased and this newly 
formed p21WAF1 is able to bind to both cycT/cdk9 and cycE/cdk2 complexes. Binding of p21WAF1 to cyclin/cdk complexes 
results in inhibition of HIV-1 LTR transcription possibly through decreased RNA Pol II and/or histone H1 phosphorylation. 
p21WAF1 can also be activated by 9AA treatment in p53 mutant cells by a yet undefined mechanism.
p21/waf1 promoter 
activity
Loss of G1/S 
checkpoint
p21/waf1 
expression
+9AA
and
/or
HIV LTR
Virus Production
?Virology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
Page 12 of 14
(page number not for citation purposes)
3. Garden GA, Morrison RS: The multiple roles of p53 in the
pathogenesis of HIV associated dementia.  Biochem Biophys Res
Commun 2005, 331:799-809.
4. Liu Y, Kulesz-Martin M: P53 regulation and function in normal
cells and tumors.  Medicina (B Aires) 2000, 60(Suppl 2):9-11.
5. Yu J, Zhang L: The transcriptional targets of p53 in apoptosis
control.  Biochem Biophys Res Commun 2005, 331:851-8.
6. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM: In vivo mito-
chondrial p53 translocation triggers a rapid first wave of cell
death in response to DNA damage that can precede p53 tar-
get gene activation.  Mol Cell Biol 2004, 24:6728-41.
7. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W,
Andreeff M: Mdm2 inhibitor Nutlin-3a induces p53-mediated
apoptosis by transcription-dependent and transcription-
independent mechanisms and may overcome Atm-medi-
ated resistance to fludarabine in chronic lymphocytic leuke-
mia.  Blood 2006, 108:993-1000.
8. Kelley ST, Coppola D, Yeatman T, Marcet J: Tumor response to
neoadjuvant chemoradiation therapy for rectal adenocarci-
noma is mediated by p53-dependent and caspase 8-depend-
ent apoptotic pathways.  Clin Colorectal Cancer 2005, 5:114-8.
9. Strachan GD, Koike MA, Siman R, Hall DJ, Jordan-Sciutto KL: E2F1
induces cell death, calpain activation, and MDMX degrada-
tion in a transcription independent manner implicating a
novel role for E2F1 in neuronal loss in SIV encephalitis.  J Cell
Biochem 2005, 96:728-40.
10. Meek DW: The role of p53 in the response to mitotic spindle
damage.  Pathol Biol (Paris) 2000, 48:246-54.
11. Bartek J, Lukas J: Pathways governing G1/S transition and their
response to DNA damage.  FEBS Lett 2001, 490:117-22.
12. Bartek J, Lukas J: Mammalian G1- and S-phase checkpoints in
response to DNA damage.  Curr Opin Cell Biol 2001, 13:738-47.
13. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J:
Deregulation of the G1/S-phase control in human testicular
germ cell tumours.  Apmis 2003, 111:252-65. discussion 265–6
14. Honma M: Generation of loss of heterozygosity and its
dependency on p53 status in human lymphoblastoid cells.
Environ Mol Mutagen 2005, 45:162-76.
15. Taylor WR, Stark GR: Regulation of the G2/M transition by p53.
Oncogene 2001, 20:1803-15.
16. Stark GR, Taylor WR: Analyzing the G2/M checkpoint.  Methods
Mol Biol 2004, 280:51-82.
17. Stark GR, Taylor WR: Control of the G2/M transition.  Mol Bio-
technol 2006, 32:227-48.
18. Houtgraaf JH, Versmissen J, Giessen WJ van der: A concise review
of DNA damage checkpoints and repair in mammalian cells.
Cardiovasc Revasc Med 2006, 7:165-72.
19. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S: Molecular
mechanisms of mammalian DNA repair and the DNA dam-
age checkpoints.  Annu Rev Biochem 2004, 73:39-85.
20. Li CY, Suardet L, Little JB: Potential role of WAF1/Cip1/p21 as a
mediator of TGF-beta cytoinhibitory effect.  J Biol Chem 1995,
270:4971-4.
21. Li CJ, Wang C, Friedman DJ, Pardee AB: Reciprocal modulations
between p53 and Tat of human immunodeficiency virus type
1.  Proc Natl Acad Sci USA 1995, 92:5461-4.
22. Duan L, Ozaki I, Oakes JW, Taylor JP, Khalili K, Pomerantz RJ: The
tumor suppressor protein p53 strongly alters human immu-
nodeficiency virus type 1 replication.  J Virol 1994, 68:4302-13.
23. Subler MA, Martin DW, Deb S: Activation of the human immu-
nodeficiency virus type 1 long terminal repeat by transform-
ing mutants of human p53.  J Virol 1994, 68:103-10.
24. el-Solh A, Kumar NM, Nair MP, Schwartz SA, Lwebuga-Mukasa JS: An
RGD containing peptide from HIV-1 Tat-(65-80) modulates
protooncogene expression in human bronchoalveolar carci-
noma cell line, A549.  Immunol Invest 1997, 26:351-70.
25. Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Fran-
chini G: Human immunodeficiency virus type-1 Tat/co-activa-
tor acetyltransferase interactions inhibit p53Lys-320
acetylation and p53-responsive transcription.  J Biol Chem 2003,
278:12310-8.
26. Longo F, Marchetti MA, Castagnoli L, Battaglia PA, Gigliani F: A novel
approach to protein-protein interaction: complex formation
between the p53 tumor suppressor and the HIV Tat pro-
teins.  Biochem Biophys Res Commun 1995, 206:326-34.
27. Clark E, Santiago F, Deng L, Chong S, de La Fuente C, Wang L, Fu P,
Stein D, Denny T, Lanka V, et al.: Loss of G(1)/S checkpoint in
human immunodeficiency virus type 1-infected cells is asso-
ciated with a lack of cyclin-dependent kinase inhibitor p21/
Waf1.  J Virol 2000, 74:5040-52.
28. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM,
Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential
mediator of p53 tumor suppression.  Cell 1993, 75:817-25.
29. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in
vivo by an associated 20K regulatory subunit.  Nature 1993,
366:707-10.
30. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21
Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyc-
lin-dependent kinases.  Cell 1993, 75:805-16.
31. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21
is a universal inhibitor of cyclin kinases.  Nature 1993,
366:701-4.
32. Ohata M, Nakamura S, Fujita H, Isemura M: Prognostic implica-
tions of p21 (Waf1/Cip1) immunolocalization in multiple
myeloma.  Biomed Res 2005, 26:91-8.
33. de Oliveira RM: Klotho RNAi induces premature senescence
of human cells via a p53/p21 dependent pathway.  FEBS Lett
2006, 580:5753-8.
34. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF: Human DNA-
(cytosine-5) methyltransferase-PCNA complex as a target
for p21WAF1.  Science 1997, 277:1996-2000.
35. Perkins ND: Not just a inhibitor CDK: regulation of transcrip-
tion by p21(WAF1/CIP1/SDI1).  Cell Cycle 2002, 1:39-41.
36. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou
HS, Fattaey A, Harlow E: New functional activities for the p21
family of CDK inhibitors.  Genes Dev 1997, 11:847-62.
37. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr
CJ: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essen-
tial activators of cyclin D-dependent kinases in murine
fibroblasts.  Embo J 1999, 18:1571-83.
38. Alt JR, Gladden AB, Diehl JA: p21(Cip1) Promotes cyclin D1
nuclear accumulation via direct inhibition of nuclear export.
J Biol Chem 2002, 277:8517-23.
39. Sebestik J, Hlavacek J, Stibor I: A role of the 9-aminoacridines
and their conjugates in a life science.  Curr Protein Pept Sci 2007,
8:471-83.
40. Phuan PW, Zorn JA, Safar J, Giles K, Prusiner SB, Cohen FE, May BC:
Discriminating between cellular and misfolded prion protein
by using affinity to 9-aminoacridine compounds.  J Gen Virol
2007, 88:1392-401.
41. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E,
Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, et al.:
Small molecules that reactivate p53 in renal cell carcinoma
reveal a NF-kappaB-dependent mechanism of p53 suppres-
sion in tumors.  Proc Natl Acad Sci USA 2005, 102:17448-53.
42. Zwelling LA: Topoisomerase II as a target of antileukemia
drugs: a review of controversial areas.  Hematol Pathol 1989,
3:101-12.
43. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman
L, Radcliffe A, Beran M, Blick M: Characterization of an amsa-
crine-resistant line of human leukemia cells. Evidence for a
drug-resistant form of topoisomerase II.  J Biol Chem 1989,
264:16411-20.
44. Sohn TA, Bansal R, Su GH, Murphy KM, Kern SE: High-throughput
measurement of the Tp53 response to anticancer drugs and
random compounds using a stably integrated Tp53-respon-
sive luciferase reporter.  Carcinogenesis 2002, 23:949-57.
45. Jung KJ, Dasgupta A, Huang K, Jeong SJ, Pise-Masison C, Gurova KV,
Brady JN: Small-molecule inhibitor which reactivates p53 in
human T-cell leukemia virus type 1-transformed cells.  J Virol
2008, 82:8537-47.
46. Wu W, Kehn-Hall K, Pedati C, Zweier L, Castro I, Klase Z, Dowd CS,
Dubrovsky L, Bukrinsky M, Kashanchi F: Drug 9AA reactivates
p21/Waf1 and Inhibits HIV-1 progeny formation.  Virol J 2008,
5:41.
47. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov
AV, Gurova KV: 9-Aminoacridine-based anticancer drugs tar-
get the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
Oncogene 2009, 28:1151-61.
48. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flan-
agan A, Teague J, Futreal PA, Stratton MR, et al.: The COSMICVirology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
Page 13 of 14
(page number not for citation purposes)
(Catalogue of Somatic Mutations in Cancer) database and
website.  Br J Cancer 2004, 91:355-8.
49. Cheng J, Haas M: Frequent mutations in the p53 tumor sup-
pressor gene in human leukemia T-cell lines.  Mol Cell Biol 1990,
10:5502-9.
50. Jeong SJ, Pise-Masison CA, Radonovich MF, Park HU, Brady JN: Acti-
vated AKT regulates NF-kappaactivation B, p53 inhibition
and cell survival in HTLV-1-transformed cells.  Oncogene 2005,
24:6719-28.
51. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB,
Cohen P: Characterization of a 3-phosphoinositide-depend-
ent protein kinase which phosphorylates and activates pro-
tein kinase Balpha.  Curr Biol 1997, 7:261-9.
52. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter
GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, et
al.: Protein kinase B kinases that mediate phosphatidylinosi-
tol 3,4,5-trisphosphate-dependent activation of protein
kinase B.  Science 1998, 279:710-4.
53. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation
and regulation of Akt/PKB by the rictor-mTOR complex.  Sci-
ence 2005, 307:1098-101.
54. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR
pathway.  Curr Opin Cell Biol 2005, 17:596-603.
55. Hresko RC, Mueckler M: mTOR.RICTOR is the Ser473 kinase
for Akt/protein kinase B in 3T3-L1 adipocytes.  J Biol Chem
2005, 280:40406-16.
56. Bayascas JR, Alessi DR: Regulation of Akt/PKB Ser473 phospho-
rylation.  Mol Cell 2005, 18:143-5.
57. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhi-
bition of glycogen synthase kinase-3 by insulin mediated by
protein kinase B.  Nature 1995, 378:785-9.
58. Logan CY, Nusse R: The Wnt signaling pathway in develop-
ment and disease.  Annu Rev Cell Dev Biol 2004, 20:781-810.
59. Shaw M, Cohen P, Alessi DR: Further evidence that the inhibi-
tion of glycogen synthase kinase-3beta by IGF-1 is mediated
by PDK1/PKB-induced phosphorylation of Ser-9 and not by
dephosphorylation of Tyr-216.  FEBS Lett 1997, 416:307-11.
60. Casamayor A, Morrice NA, Alessi DR: Phosphorylation of Ser-
241 is essential for the activity of 3-phosphoinositide-
dependent protein kinase-1: identification of five sites of
phosphorylation in vivo.  Biochem J 1999, 342(Pt 2):287-92.
61. Li Y, Dowbenko D, Lasky LA: AKT/PKB phosphorylation of
p21Cip/WAF1 enhances protein stability of p21Cip/WAF1
and promotes cell survival.  J Biol Chem 2002, 277:11352-61.
62. Child ES, Mann DJ: The intricacies of p21 phosphorylation: pro-
tein/protein interactions, subcellular localization and stabil-
ity.  Cell Cycle 2006, 5:1313-9.
63. Verschuren EW, Jones N, Evan GI: The cell cycle and how it is
steered by Kaposi's sarcoma-associated herpesvirus cyclin.  J
Gen Virol 2004, 85:1347-61.
64. Castedo M, Ferri KF, Blanco J, Roumier T, Larochette N, Barretina J,
Amendola A, Nardacci R, Metivier D, Este JA, et al.: Human immu-
nodeficiency virus 1 envelope glycoprotein complex-induced
apoptosis involves mammalian target of rapamycin/FKBP12-
rapamycin-associated protein-mediated p53 phosphoryla-
tion.  J Exp Med 2001, 194:1097-110.
65. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, Tintignac LA,
Andreau K, Perfettini JL, Amendola A, Nardacci R, et al.: Sequential
involvement of Cdk1, mTOR and p53 in apoptosis induced
by the HIV-1 envelope.  Embo J 2002, 21:4070-80.
66. Perfettini JL, Roumier T, Castedo M, Larochette N, Boya P, Raynal B,
Lazar V, Ciccosanti F, Nardacci R, Penninger J, et al.: NF-kappaB and
p53 are the dominant apoptosis-inducing transcription fac-
tors elicited by the HIV-1 envelope.  J Exp Med 2004,
199:629-40.
67. Pauls E, Senserrich J, Clotet B, Este JA: Inhibition of HIV-1 repli-
cation by RNA interference of p53 expression.  J Leukoc Biol
2006, 80:659-67.
68. Zhang J, Scadden DT, Crumpacker CS: Primitive hematopoietic
cells resist HIV-1 infection via p21.  J Clin Invest 2007,
117:473-81.
69. Shen H, Cheng T, Preffer FI, Dombkowski D, Tomasson MH, Golan
DE, Yang O, Hofmann W, Sodroski JG, Luster AD, et al.: Intrinsic
human immunodeficiency virus type 1 resistance of hemat-
opoietic stem cells despite coreceptor expression.  J Virol
1999, 73:728-37.
70. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC, Reitz MS Jr:
HIV-1 protease inhibitor ritonavir modulates susceptibility
to apoptosis of uninfected T cells.  J Hum Virol 1999, 2:261-9.
71. Lee B, Ratajczak J, Doms RW, Gewirtz AM, Ratajczak MZ: Corecep-
tor/chemokine receptor expression on human hematopoi-
etic cells: biological implications for human
immunodeficiency virus-type 1 infection.  Blood 1999,
93:1145-56.
72. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J:
TRIM5alpha mediates the postentry block to N-tropic
murine leukemia viruses in human cells.  Proc Natl Acad Sci USA
2004, 101:11827-32.
73. Keckesova Z, Ylinen LM, Towers GJ: The human and African
green monkey TRIM5alpha genes encode Ref1 and Lv1 ret-
roviral restriction factor activities.  Proc Natl Acad Sci USA 2004,
101:10780-5.
74. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J:
Binding and susceptibility to postentry restriction factors in
monkey cells are specified by distinct regions of the human
immunodeficiency virus type 1 capsid.  J Virol 2004, 78:5423-37.
75. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski
J:  The cytoplasmic body component TRIM5alpha restricts
HIV-1 infection in Old World monkeys.  Nature 2004,
427:848-53.
76. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human
gene that inhibits HIV-1 infection and is suppressed by the
viral Vif protein.  Nature 2002, 418:646-50.
77. Gartel AL, Tyner AL: Transcriptional regulation of the
p21((WAF1/CIP1)) gene.  Exp Cell Res 1999, 246:280-9.
78. Gartel AL, Radhakrishnan SK: Lost in transcription: p21 repres-
sion, mechanisms, and consequences.  Cancer Res 2005,
65:3980-5.
79. Rohr O, Marban C, Aunis D, Schaeffer E: Regulation of HIV-1
gene transcription: from lymphocytes to microglial cells.  J
Leukoc Biol 2003, 74:736-49.
80. Michael D, Oren M: The p53-Mdm2 module and the ubiquitin
system.  Semin Cancer Biol 2003, 13:49-58.
81. Yang Y, Li CC, Weissman AM: Regulating the p53 system
through ubiquitination.  Oncogene 2004, 23:2096-106.
82. Brooks CL, Gu W: Dynamics in the p53-Mdm2 ubiquitination
pathway.  Cell Cycle 2004, 3:895-9.
83. Brooks CL, Gu W: p53 ubiquitination: Mdm2 and beyond.  Mol
Cell 2006, 21:307-15.
84. Marchenko ND, Moll UM: The role of ubiquitination in the
direct mitochondrial death program of p53.  Cell Cycle 2007,
6:1718-23.
85. Blattner C, Hay T, Meek DW, Lane DP: Hypophosphorylation of
Mdm2 augments p53 stability.  Mol Cell Biol 2002, 22:6170-82.
86. Kulikov R, Boehme KA, Blattner C: Glycogen synthase kinase 3-
dependent phosphorylation of Mdm2 regulates p53 abun-
dance.  Mol Cell Biol 2005, 25:7170-80.
87. Boehme KA, Kulikov R, Blattner C: p53 stabilization in response
to DNA damage requires Akt/PKB and DNA-PK.  Proc Natl
Acad Sci USA 2008, 105:7785-90.
88. Rossig L, Jadidi AS, Urbich C, Badorff C, Zeiher AM, Dimmeler S:
Akt-dependent phosphorylation of p21(Cip1) regulates
PCNA binding and proliferation of endothelial cells.  Mol Cell
Biol 2001, 21:5644-57.
89. Oh YT, Chun KH, Park BD, Choi JS, Lee SK: Regulation of cyclin-
dependent kinase inhibitor p21WAF1/CIP1 by protein
kinase Cdelta-mediated phosphorylation.  Apoptosis 2007,
12:1339-47.
90. Garcia-Martinez LF, Mavankal G, Neveu JM, Lane WS, Ivanov D,
Gaynor RB: Purification of a Tat-associated kinase reveals a
TFIIH complex that modulates HIV-1 transcription.  Embo J
1997, 16:2836-50.
91. Nekhai S, Shukla RR, Kumar A: A human primary T-lymphocyte-
derived human immunodeficiency virus type 1 Tat-associ-
ated kinase phosphorylates the C-terminal domain of RNA
polymerase II and induces CAK activity.  J Virol 1997,
71:7436-41.
92. Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM:
The human immunodeficiency virus transactivator Tat
interacts with the RNA polymerase II holoenzyme.  Mol Cell
Biol 1997, 17:1817-23.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:114 http://www.virologyj.com/content/6/1/114
Page 14 of 14
(page number not for citation purposes)
93. Cujec TP, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan
DO, Peterlin BM: The HIV transactivator TAT binds to the
CDK-activating kinase and activates the phosphorylation of
the carboxy-terminal domain of RNA polymerase II.  Genes
Dev 1997, 11:2645-57.
94. Parada CA, Roeder RG: Enhanced processivity of RNA
polymerase II triggered by Tat-induced phosphorylation of
its carboxy-terminal domain.  Nature 1996, 384:375-8.
95. Zhou C, Rana TM: A bimolecular mechanism of HIV-1 Tat pro-
tein interaction with RNA polymerase II transcription elon-
gation complexes.  J Mol Biol 2002, 320:925-42.
96. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA: A novel CDK9-
associated C-type cyclin interacts directly with HIV-1 Tat
and mediates its high-affinity, loop-specific binding to TAR
RNA.  Cell 1998, 92:451-62.
97. Wimmer J, Fujinaga K, Taube R, Cujec TP, Zhu Y, Peng J, Price DH,
Peterlin BM: Interactions between Tat and TAR and human
immunodeficiency virus replication are facilitated by human
cyclin T1 but not cyclins T2a or T2b.  Virology 1999, 255:182-9.
98. Zhou M, Halanski MA, Radonovich MF, Kashanchi F, Peng J, Price DH,
Brady JN: Tat modifies the activity of CDK9 to phosphorylate
serine 5 of the RNA polymerase II carboxyl-terminal domain
during human immunodeficiency virus type 1 transcription.
Mol Cell Biol 2000, 20:5077-86.
99. Chen D, Zhou Q: Tat activates human immunodeficiency
virus type 1 transcriptional elongation independent of TFIIH
kinase.  Mol Cell Biol 1999, 19:2863-71.
100. Nguyen VT, Kiss T, Michels AA, Bensaude O: 7SK small nuclear
RNA binds to and inhibits the activity of CDK9/cyclin T com-
plexes.  Nature 2001, 414:322-5.
101. Michels AA, Nguyen VT, Fraldi A, Labas V, Edwards M, Bonnet F,
Lania L, Bensaude O: MAQ1 and 7SK RNA interact with CDK9/
cyclin T complexes in a transcription-dependent manner.
Mol Cell Biol 2003, 23:4859-69.
102. Yang Z, Zhu Q, Luo K, Zhou Q: The 7SK small nuclear RNA
inhibits the CDK9/cyclin T1 kinase to control transcription.
Nature 2001, 414:317-22.
103. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q: Inhibition
of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II
transcription by the coordinated actions of HEXIM1 and 7SK
snRNA.  Mol Cell 2003, 12:971-82.
104. Michels AA, Fraldi A, Li Q, Adamson TE, Bonnet F, Nguyen VT,
Sedore SC, Price JP, Price DH, Lania L, et al.: Binding of the 7SK
snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyc-
lin T) inhibitor.  Embo J 2004, 23:2608-19.
105. Fraldi A, Varrone F, Napolitano G, Michels AA, Majello B, Bensaude
O, Lania L: Inhibition of Tat activity by the HEXIM1 protein.
Retrovirology 2005, 2:42.
106. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ: Novel INK4
proteins, p19 and p18, are specific inhibitors of the cyclin D-
dependent kinases CDK4 and CDK6.  Mol Cell Biol 1995,
15:2672-81.
107. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-
cycle control causing specific inhibition of cyclin D/CDK4.
Nature 1993, 366:704-7.
108. Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'Keefe CL, Matera
AG, Xiong Y: Growth suppression by p18, a p16INK4/MTS1-
and p14INK4B/MTS2-related CDK6 inhibitor, correlates
with wild-type pRb function.  Genes Dev 1994, 8:2939-52.
109. Chan FK, Zhang J, Cheng L, Shapiro DN, Winoto A: Identification
of human and mouse p19, a novel CDK4 and CDK6 inhibitor
with homology to p16ink4.  Mol Cell Biol 1995, 15:2682-8.
110. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM,
Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent
kinase inhibitor and a potential mediator of extracellular
antimitogenic signals.  Cell 1994, 78:59-66.
111. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper
JW, Elledge SJ: p57KIP2, a structurally distinct member of the
p21CIP1 Cdk inhibitor family, is a candidate tumor suppres-
sor gene.  Genes Dev 1995, 9:650-62.
112. Dickinson LA, Edgar AJ, Ehley J, Gottesfeld JM: Cyclin L is an RS
domain protein involved in pre-mRNA splicing.  J Biol Chem
2002, 277:25465-73.